儿童哮喘急性发作治疗指南推荐分析:儿科急诊研究网络(PERN)研究
该观察性研究分析了来自全球六个区域儿科急诊研究网络的158部儿童哮喘急性发作管理指南。半数指南提供至少两个年龄组的推荐,多数按哮喘严重程度给出治疗建议。吸入短效β受体激动剂和全身糖皮质激素的推荐一致;吸入抗胆碱能治疗在多数指南中推荐用于重度和危重度哮喘,但对轻中度发作推荐不一致;氦氧混合气(Heliox)和雾化镁等吸入疗法对重度和危重度疾病的推荐不一致;肠外支气管扩张剂和肾上腺素多保留用于重度和危重度哮喘,其中静脉镁最常被推荐,其他肠外支气管扩张剂(尤其是氨茶碱)的使用存在区域差异。指南质量评估显示,表述清晰度、范围与目的评分高,但利益相关方参与、制定严谨性、适用性和编辑独立性评分低。结论指出当前指南在重要质量领域存在明显缺陷,对重症发作的指导有限且不一致。
要点
- 全球158部儿童哮喘急性发作指南中,吸入短效β受体激动剂和全身糖皮质激素的推荐一致。
- 吸入抗胆碱能治疗在多数指南中推荐用于重度和危重度哮喘,但对轻中度发作推荐不一致。
- 氦氧混合气(Heliox)和雾化镁对重度和危重度疾病的推荐不一致。
- 肠外支气管扩张剂和肾上腺素多保留用于重度和危重度哮喘,静脉镁最常被推荐;其他肠外支气管扩张剂(尤其是氨茶碱)使用存在区域差异。
- 指南质量在利益相关方参与、制定严谨性、适用性和编辑独立性方面评分低。
适用人群与场景
- 儿童哮喘急性发作患者,指南涵盖至少两个年龄组(半数指南),多数指南按哮喘严重程度(轻度、中度、重度、危重度)给出治疗推荐。
处置流程与药物剂量
- 吸入短效β受体激动剂和全身糖皮质激素:指南推荐一致。
- 吸入抗胆碱能治疗:多数指南推荐用于重度和危重度哮喘;对轻度和中度发作的推荐不一致。
- 氦氧混合气(Heliox)和雾化镁:对重度和危重度疾病的推荐不一致。
- 肠外支气管扩张剂和肾上腺素:多保留用于重度和危重度哮喘,其中静脉镁最常被推荐;其他肠外支气管扩张剂(尤其是氨茶碱)的使用存在区域差异。
研究设计与关键结果
- 研究类型:观察性研究,分析来自全球六个区域儿科急诊研究网络的158部指南。
- 半数指南提供至少两个年龄组的推荐,多数指南按哮喘严重程度给出治疗推荐。
- 吸入短效β受体激动剂和全身糖皮质激素推荐一致;吸入抗胆碱能治疗对重度和危重度推荐一致,对轻中度推荐不一致;氦氧混合气(Heliox)和雾化镁对重度和危重度推荐不一致;肠外支气管扩张剂和肾上腺素多保留用于重度和危重度,静脉镁最常被推荐,其他肠外支气管扩张剂(尤其是氨茶碱)使用存在区域差异。
- 指南质量评估:表述清晰度、范围与目的评分高;利益相关方参与、制定严谨性、适用性和编辑独立性评分低。
证据类型、等级与局限
- 证据类型:观察性研究(指南分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 当前指南在重要质量领域存在明显缺陷,对重症发作的指导有限且不一致,作者认为这可能是临床实践差异的原因之一。
指南或共识出处
- 儿科急诊研究网络(PERN)研究,分析全球六个区域儿科急诊研究网络的158部儿童哮喘急性发作管理指南。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: There is significant practice variation in acute paediatric asthma, particularly severe exacerbations. It is unknown whether this is due to differences in clinical guidelines.
OBJECTIVES: To describe and compare the content and quality of clinical guidelines for the management of acute exacerbations of asthma in children between geographic regions.
METHODS: Observational study of guidelines for the management of acute paediatric asthma from institutions across a global collaboration of six regional paediatric emergency research networks.
MEASUREMENTS AND MAIN RESULTS: 158 guidelines were identified. Half provided recommendations for at least two age groups, and most guidelines provided treatment recommendations according to asthma severity.There were consistent recommendations for the use of inhaled short-acting beta-agonists and systemic corticosteroids. Inhaled anticholinergic therapy was recommended in most guidelines for severe and critical asthma, but there were inconsistent recommendations for its use in mild and moderate exacerbations. Other inhaled therapies such as helium-oxygen mixture (Heliox) and nebulised magnesium were inconsistently recommended for severe and critical illness.Parenteral bronchodilator therapy and epinephrine were mostly reserved for severe and critical asthma, with intravenous magnesium most recommended. There were regional differences in the use of other parenteral bronchodilators, particularly aminophylline.Guideline quality assessment identified high ratings for clarity of presentation, scope and purpose, but low ratings for stakeholder involvement, rigour of development, applicability and editorial independence.
CONCLUSIONS: Current guidelines for the management of acute paediatric asthma exacerbations have substantial deficits in important quality domains and provide limited and inconsistent guidance for severe exacerbations.
参考来源
- Craig S, Collings M, Gray C, et al. Analysis of guideline recommendations for treatment of asthma exacerbations in children: a Pediatric Emergency Research Networks (PERN) study. Arch Dis Child. 2024. PMID: 38325912. doi:10.1136/archdischild-2023-326739
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。